News
UCBJY
158.51
+0.34%
0.54
UCB SA (0NZT) Receives a Buy from UBS
TipRanks · 4d ago
Weekly Report: what happened at UCBJY last week (0601-0605)?
Weekly Report · 5d ago
Weekly Report: what happened at UCBJY last week (0525-0529)?
Weekly Report · 06/01 10:43
UCB SA (0NZT) Gets a Buy from Barclays
TipRanks · 05/28 06:46
Weekly Report: what happened at UCBJY last week (0518-0522)?
Weekly Report · 05/25 10:48
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial
Seeking Alpha · 05/19 13:52
Weekly Report: what happened at UCBJY last week (0511-0515)?
Weekly Report · 05/18 10:47
UCB SA (0NZT) Receives a Buy from Barclays
TipRanks · 05/18 09:25
Weekly Report: what happened at UCBJY last week (0504-0508)?
Weekly Report · 05/11 10:44
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 05/11 06:27
Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 05/05 06:16
Cullinan jumps after UCB acquires Candid Therapeutics
TipRanks · 05/04 14:27
Weekly Report: what happened at UCBJY last week (0427-0501)?
Weekly Report · 05/04 10:40
Weekly Report: what happened at UCBJY last week (0420-0424)?
Weekly Report · 04/27 10:44
UCB SA (0NZT) Receives a Buy from Barclays
TipRanks · 04/27 06:45
Weekly Report: what happened at UCBJY last week (0413-0417)?
Weekly Report · 04/20 10:38
Barclays Remains a Buy on UCB SA (0NZT)
TipRanks · 04/20 06:25
Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B
Seeking Alpha · 04/17 18:33
UCB to acquire Neurona Therapeutics
TipRanks · 04/17 17:06
Weekly Report: what happened at UCBJY last week (0406-0410)?
Weekly Report · 04/13 10:43
More
Webull provides a variety of real-time UCBJY stock news. You can receive the latest news about Ucb S A through multiple platforms. This information may help you make smarter investment decisions.
About UCBJY
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.